期刊
MOLECULAR ONCOLOGY
卷 17, 期 1, 页码 82-97出版社
WILEY
DOI: 10.1002/1878-0261.13337
关键词
CLL; p53; phosphorylation
类别
Abnormalities in the TP53 gene are the most significant biomarker in chronic lymphocytic leukemia (CLL). Changes in p53 protein modifications can also influence its function, even in the wild-type protein. This study explores the impact of p53 protein phosphorylations on p53 function and suggests that reduced phosphorylation of wild-type p53 in CLL cells leads to behavior similar to TP53 mutants after DNA damage. These findings are linked to ATM locus defects and higher basal activity of the hypoxia pathway.
TP53 gene abnormalities represent the most important biomarker in chronic lymphocytic leukemia (CLL). Altered protein modifications could also influence p53 function, even in the wild-type protein. We assessed the impact of p53 protein phosphorylations on p53 functions as an alternative inactivation mechanism. We studied p53 phospho-profiles induced by DNA-damaging agents (fludarabine, doxorubicin) in 71 TP53-intact primary CLL samples. Doxorubicin induced two distinct phospho-profiles: profile I (heavily phosphorylated) and profile II (hypophosphorylated). Profile II samples were less capable of activating p53 target genes upon doxorubicin exposure, resembling TP53-mutant samples at the transcriptomic level, whereas standard p53 signaling was triggered in profile I. ATM locus defects were more common in profile II. The samples also differed in the basal activity of the hypoxia pathway: the highest level was detected in TP53-mutant samples, followed by profile II and profile I. Our study suggests that wild-type TP53 CLL cells with less phosphorylated p53 show TP53-mutant-like behavior after DNA damage. p53 hypophosphorylation and the related lower ability to respond to DNA damage are linked to ATM locus defects and the higher basal activity of the hypoxia pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据